AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05227963 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: neck isometric strengthening exercises
Description: In this group, each participant received 20-minutes long session. Each session started in seated position and participants were asked to perform flexion, extension, side bending and rotation against resistance. During flexion movement, therapist placed hand on forehead and asked patient to move the neck forward, while in extension, therapist hand was placed at back of the head and patient had to move neck in backward direction. However, in side bending and rotation- therapist hand was placed at lateral side of the head and asked patient to side bend the neck and look at shoulder in the same direction respectively. Each session was repeated four-times a week for two-weeks (a total eight sessions).
Study NCT05227963 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neck isometric strengthening exercises
Description: In this group, each participant received 20-minutes long session. Each session started in seated position and participants were asked to perform flexion, extension, side bending and rotation against resistance. During flexion movement, therapist placed hand on forehead and asked patient to move the neck forward, while in extension, therapist hand was placed at back of the head and patient had to move neck in backward direction. However, in side bending and rotation- therapist hand was placed at lateral side of the head and asked patient to side bend the neck and look at shoulder in the same direction respectively. Each session was repeated four-times a week for two-weeks (a total eight sessions).
Study NCT01218451 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal 13-valent conjugate vaccine
Description: 0.5 mL dose, subcutaneous administration in right anterolateral thigh
Study NCT01218451 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal 13-valent conjugate vaccine
Description: 0.5 mL dose, subcutaneous administration in right anterolateral thigh
Study NCT01218451 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine
Description: 0.5 mL dose, subcutaneous administration in right anterolateral thigh
Study NCT01218451 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine
Description: 0.5 mL dose, subcutaneous administration in right anterolateral thigh
Study NCT02022592 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Study NCT03652506 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: regional oxymetry probe
Description: The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
Study NCT04274153 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gardasil9
Description: Two doses of the HPV vaccine across a 12 month period (two doses of 0.5mL).
Study NCT01238835 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAPIEN XT™ Transapical aortic valve replacement
Description: Transcatheter aortic valve implantation via the transapical approach
Study NCT00908648 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Narrow Band Imaging
Description: Narrow Band Imaging
Study NCT01966588 — intervention group
Intervention type: OTHER
Intervention: Blood samples for whole genomic/transcriptomic sequencing
Description: Participants in the Metabolic Arm will receive one blood draw, while participants in the Neutropenia Arm will receive a total of three blood draws: one at baseline, another 3 months later, and one 1 year later, with the possibility of further follow-up.
Study NCT03652506 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus Lumborum block
Description: Ultrasound guided unilateral anterior Quadratus Lumborum block with 20 ml %0.25 bupivacaine+The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
Study NCT01966588 — intervention group
Intervention type: OTHER
Intervention: UKU Side Effect Rating Scale
Description: Clinician-rated scale of psychic, neurological, autonomic, and other side effects related to psychotropic drugs; ratings are based on a 10-30 minute interview with each participant.
Study NCT03652506 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Epidural block
Description: Thoracic Epidural block with 20 ml %0.25 bupivacaine+The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
Study NCT01914991 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dynamic extension contracture orthotic
Description: A dynamic orthosis was constructed in the experimental group using the same style of dynamic extension contracture orthotic. A mobilizing force of 250 - 300 gm/cm2 was set in each one. Patients were instructed to wear it for at least 6 hours per day and then removed it for ADL (Activity Daily Living). A static orthosis was constructed using orfitcast material to the maximum, pain-free length allowed by the tissues at night. Static and dynamic orthoses were checked once a week and adjusted as necessary.
Study NCT01914991 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional treatment Physical Therapy
Description: Traditional treatment was applied to one control group. The treatment consisted of 10 minutes of local thermotherapy (paraffin), active exercises at the PIPJ and DIPJ (Distal interphalangeal joint), 3 sets of 15 repetitions of each exercise extending and flexing of the PIPJ with metacarpophalangeal joint from 0° to 90° respectively. Distal interphalangeal joint exercises were conducted with identical repetitions. The metacarpophalangeal joint and PIPJ exercises took place at 0 ° and involved stretching (5 sets of 3 reps, holding for 10 seconds) and Therapeutic U.S (0.8 w/cm2 / 7 minutes).
Study NCT00661206 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Patients on clopidogrel therapy at 6 months after implantation of a drug-eluting stent will be randomized to an additional 6 month period of clopidogrel 75mg per day
Study NCT00661206 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients randomized in this group will receive placebo for 6 months.
Study NCT00695188 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: methotrexate
Description: oral administration Escalating dose (15, 20, 25 mg)
Study NCT03844529 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sunmax FULLSGEN with Lidocaine
Description: Subject who voluntarily sign the informed consent form (day -14\~1) will be randomly assigned to investigational or control group and have intradermal allergy test. After the injection treatment by randomly choosing the device, every subject would have 6 follow-up visits.
Study NCT02946047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib 2 MG
Description: 2mg on days 1, 8 and 15 for three 28 days cycles, then be reviewed by DSMB and based upon their recommendation patients will receive ixazomib once weekly for 12 weeks or ixazomib 2 mg on days 1, 8 and 15 for three 28 days cycles. Visits 3-15 will have a window of ± 3 days.
Study NCT02946047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib 3 MG
Description: 3 mg on days 1, 8 and 15 for three 28 days cycles, then be reviewed by DSMB and based upon their recommendation patients will receive ixazomib once weekly for 12 weeks or ixazomib 3 mg on days 1, 8 and 15 for three 28 days cycles. Visits 3-15 will have a window of ± 3 days.
Study NCT02946047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib 4 MG
Description: 4 mg on days 1, 8 and 15 for three 28 days cycles, then be reviewed by DSMB and based upon their recommendation patients will receive ixazomib once weekly for 12 weeks or ixazomib 4 mg on days 1, 8 and 15 for three 28 days cycles. Visits 3-15 will have a window of ± 3 days.
Study NCT01011660 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine, Telmisartan, Amiloride Compound , Simvastatin
Description: Amlodipine; Telmisartan; Amiloride Compound; Simvastatin
Study NCT03844529 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sunmax FULLSGEN with Lidocaine
Description: Subject who voluntarily sign the informed consent form (day -14\~1) will be randomly assigned to investigational or control group and have intradermal allergy test. After the injection treatment by randomly choosing the device, every subject would have 6 follow-up visits.
Study NCT02868801 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: same intervention as the experimental group
Study NCT02868801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin SR tablet 165mg/day
Description: According to the efficacy and safety in titration
Study NCT02868801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin SR tablet 330mg/day
Description: According to the efficacy and safety in titration
Study NCT03242772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amphetamine
Description: Study drug will be administered in the morning. Treatment will be initiated at 1 tablet = 3.1 mg or 0 mg of mixed amphetamine. Doses will be flexibly titrated upward and may be decreased or stopped at any time.
Study NCT03242772 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ESDM informed parent coaching
Description: All participants will receive 8 weekly parent child therapy sessions will be delivered by a therapist trained in parent coaching and ESDM principles and strategies and utilizing a therapy manual,(includes coaching for behavior management and handouts).
Study NCT03242772 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: ESDM informed parent coaching
Description: All participants will receive 8 weekly parent child therapy sessions will be delivered by a therapist trained in parent coaching and ESDM principles and strategies and utilizing a therapy manual,(includes coaching for behavior management and handouts).
Study NCT03242772 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Matched placebo tablets will be administered in the morning and provided for 11 weeks . The tablets will be titrated in the same way as the active drug and may be stopped at any time.
Study NCT01770379 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab (AIN457)
Description: Secukinumab is a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a messenger protein in the body) called Interleukin 17 (IL-17)
Study NCT01770379 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00421187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (AmBisome®)
Study NCT00421187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal amphotericin B (AmBisome®)
Study NCT01882517 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Yogurt that contains plant stanol esters
Study NCT01882517 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo yogurt
Study NCT05516784 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Comparison of platelet reactivity between clopidogrel and ticagrelor
Study NCT05516784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Comparison of platelet reactivity between clopidogrel and ticagrelor
Study NCT00695188 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: 25 mg oral administration
Study NCT00487045 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hem-Avert Perianal Stabilizer
Description: Hem-Avert Perianal Stabilizer, TNP-01L, single-use, disposable, sterile, individually packaged instrument
Study NCT00853593 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pacing Lead
Description: implant and follow-up of study device
Study NCT01961076 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: overnight nutrition regime
Description: Patients receive the specified overnight nutrition regimen
Study NCT05516784 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Comparison of platelet reactivity between clopidogrel and ticagrelor
Study NCT05516784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Comparison of platelet reactivity between clopidogrel and ticagrelor
Study NCT03552211 — intervention group
Intervention type: DRUG
Intervention: biotin
Description: This is a national, academic, observational and retrospective study comparing one group of progressive MS patients with high dose biotin to another group without this treatment using a propensity score, in intention to treat.
Study NCT01364662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPN-810
Description: administered orally
Study NCT00622700 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Teriflunomide
Description: Film-coated tablet Oral administration
Study NCT00622700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriflunomide
Description: Film-coated tablet Oral administration
Study NCT02868801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin SR tablet 660mg/day
Description: According to the efficacy and safety in titration.
Study NCT03058276 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Retrieval-Extinction Learning
Description: The intervention consists of the accomplishment of the task of approach-avoidance of alcohol during 4 days of training. Subjects are instructed to respond with an approach movement (pulling a lever) to neutral images and to respond with avoidance movement (pushing the lever) to images of alcohol.
Study NCT03058276 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Retrieval-Extinction Learning
Description: The intervention consists of the accomplishment of the task of approach-avoidance of alcohol during 4 days of training. Subjects are instructed to respond with an approach movement (pulling a lever) to neutral images and to respond with avoidance movement (pushing the lever) to images of alcohol.
Study NCT03058276 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Previous to rTMS completion, MRI scans were performed in order to determinate the motor threshold trough 1Hz stimuli and locate the desired area with the neuronavigator. Motor threshold is defined as the stimulus with less intensity, able to generate a motor potential of at least 50 µV in 10 trials. Next, patients were called for 5 times per week, along 2 weeks, for receiving brain stimulation with Magstim Rapid coil. rTMS is performed at 10 Hz, during 4.9 seconds,for each set of stimuli (20), with a interval between sets of 30 seconds.
Study NCT03058276 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: SAM
Description: Previous to rTMS completion, MRI scans were performed in order to determinate the motor threshold trough 1Hz stimuli and locate the desired area with the neuronavigator. Motor threshold is defined as the stimulus with less intensity, able to generate a motor potential of at least 50 µV in 10 trials. Next, patients were called for 5 times per week, along 2 weeks, for receiving brain stimulation with SAM coil.
Study NCT02532816 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrient dense complementary foods
Description: Mothers/caregivers will receive optimized CFRs to improve children diets and fortified biscuits (3 types of biscuit) for 6 days per week (in 12 months).~Nutrition eduction for mothers/caregivers. Monthly body weight and length/height measurements
Study NCT02532816 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nutrient dense complementary foods
Description: Mothers/caregivers will receive optimized CFRs to improve children diets and fortified biscuits (3 types of biscuit) for 6 days per week (in 12 months).~Nutrition eduction for mothers/caregivers. Monthly body weight and length/height measurements
Study NCT02532816 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutrient dense complementary foods
Description: Mothers/caregivers will receive optimized CFRs to improve children diets and fortified biscuits (3 types of biscuit) for 6 days per week (in 12 months).~Nutrition eduction for mothers/caregivers. Monthly body weight and length/height measurements
Study NCT01553695 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionary
Description: Subjects have to fill out a booklet of questionnaires
Study NCT01553695 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionary
Description: Subjects have to fill out a booklet of questionnaires
Study NCT03634852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin hydrochloride 0.5% eye drops
Description: were prescribed four times a day for 1-month postoperatively
Study NCT03634852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 0.1% eye drops
Description: were prescribed four times a day for 1-month postoperatively
Study NCT03634852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intracameral Moxifloxacin 0.1%
Description: Auromox (0.5%): is a sterile clear yellow pale colored preservative free isotonic ophthalmic solution with pH 6.0 to 7.5 and osmolarity 620 -320 milliosmol ( mOsm).The sterile Auromox vial contains 1cc Moxifloxacin hydrochloride 5.45 mg equivalent to 5mg of Moxifloxacin. This product is manufactured by Aurolab an Indian pharmaceutical company. Auromox is available in many countries including Iraq.~Each vial enough for 15 different patients by using a sterile needle and 5cc syringe. By the sterile hand's, the surgeon draws the whole 1cc of Moxifloxacin 0.5% and diluted with 4 cc of balanced salt solution (BSS) to get 5 mg in 5 cc (0.1%) then draw 0.2 cc for each patient.
Study NCT03634852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subconjunctival Triamcinolone acetonide 4 mg /0.4 ml
Description: Aurocort is a preservative-free Triamcinolone acetonide (40 mg /1cc), with along acting depot preparation of triamcinolone in 1cc vial also the product of Aurolab company and commercially available in our country.~The whole 1cc had been drawn and diluted with 3cc of BSS and SC injection of 4 mg in 0.4 cc of Triamcinolone was given (as a final step in the surgery) 6mm from the limbus usually an inferotemporal site that is easily accessible and the plaque that formed will be not visible within palpebral fissure
Study NCT04681742 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CO-OP Group
Description: CO-OP focuses on learning of a global problem-solving strategy, Goal-Plan-Do-Check (GPDC), within the performance of participant-chosen goals. Use of a broadly applicable strategy and meaningful activity ensures the intervention is salient to the participant and increases likelihood of transfer. Uniquely, therapists applying CO-OP use guided discovery methods, such as asking a series of probing questions, to support participants in analyzing their own performance of a given task and generating potential solutions for improving performance. Participants become equipped with these skills through repetitive application of the GPDC process. First, participants identify a specific goal (Goal). Then, participants consider a detailed plan (Plan) for accomplishing the goal. By carrying out the plan (Do) and critically analyzing the results (Check), participants determine how the plan worked. The intervention focuses on learning GPDC with gradual withdrawal of guided discovery methods.
Study NCT01097564 — intervention group
Intervention type: GENETIC
Intervention: COL4A1 genetic testing
Description: genetic testing
Study NCT03745391 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: MULTIMODAL MAGNETIC RESONANCE (Multimodal MR)
Description: After randomization, a MULTIMODAL MR will be performed to select treatment patient
Study NCT03552211 — intervention group
Intervention type: OTHER
Intervention: propensity score
Description: This is a national, academic, observational and retrospective study comparing one group of progressive MS patients with high dose biotin to another group without this treatment using a propensity score, in intention to treat.
Study NCT02885857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shenyan Kangfu Tablet
Description: Observation period: 24 weeks. The dosage regimen: each piece weighs 0.48 g. 5 / time, 3 times daily, orally after dinner.
Study NCT03372551 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: somofilcon A 1 day test lens
Description: Contact lens
Study NCT03372551 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: somofilcon A 1 day test lens
Description: Contact lens
Study NCT03372551 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: somofilcon A 1 day control lens
Description: Contact lens
Study NCT03372551 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: somofilcon A 1 day control lens
Description: Contact lens